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Abstract The growth suppressor protein p53 plays a main part
in cellular growth control. Two of its key functions are sequence
specific DNA binding and transactivation. Functions of p53 in
growth control are regulated at least in part by its interaction
with protein kinases. p53 binds to protein kinase CK2, formerly
known as casein kinase 2, and it is phosphorylated by this
enzyme. CK2 is composed of two regulating L-subunits and two
catalytic K- or KP-subunits and the interaction with p53 is
mediated by the regulatory L-subunit of CK2. Recently we
showed that the L-subunit could inhibit the sequence specific
DNA binding activity of p53 in vitro. Based on this finding, we
asked if a coexpression of the L-subunit of CK2 with p53 in
mammalian cells could inhibit the DNA binding activity of p53 in
a physiological context. We found that the coexpression of the L-
subunit showed the same inhibitory effect as in the previous
assays with purified proteins. Then, we investigated the effects of
the coexpression of the L-subunit of CK2 on the transactivation
and transrepression activity of p53. We found that transactiva-
tion of the mdm2, p21WAF1=CIP1 and cyclin G promoter was
inhibited in three different cell lines whereas transactivation of
the bax promoter was not affected in COS1 cells but down-
regulated in MCO1 and SaosS138V21 cells. p53 mediated
transrepression of the fos promoter was not influenced by
coexpression of the CK2 L-subunit. Taken together we propose a
cell type dependent fine regulation of the p53 transactivation
function by the CK2 L-subunit in vivo, which does not affect p53
mediated transrepression.
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1. Introduction
The growth suppressor protein p53 is an important cellular
protein which governs the integrity of the human genome. It
regulates cell growth, DNA repair and apoptosis (for review
see [1,2]) at least in part because p53 is a potent transcrip-
tional regulator. p53 can transactivate the expression of genes
whose products are actively implicated in growth arrest, DNA
repair or programmed cell death and it can repress the pro-
moters of many cellular genes which are involved in stimulat-
ing growth or blocking apoptosis [3^5] or which are impli-
cated in a self-regulating loop such as the mdm2 gene
product [6]. p53 regulates transcription by binding to speci¢c
DNA sequences [7^9] or by interacting with transcription fac-
tors [10^13].
A number of di¡erent p53 responsive promoters were de-
scribed which include the promoters of p21WAF1=CIP1 [14],
mdm2 [15], cyclin G [16], EGR-1 [17] and bax [18]. On the
other hand the basal c-fos promoter and the bcl-2 promoter
are down-regulated by p53 [19,20]. So far it is not clear how
these di¡erent speci¢cities of p53 are regulated.
The polypeptide chain of p53 consists of di¡erent functional
domains [21] where an internal domain is required for contact
with speci¢c DNA sequences. A carboxy-terminal region is
able to bind non-speci¢cally to DNA [22] and to regulate
the speci¢c DNA binding activity. Binding of the p53 speci¢c
monoclonal antibody PAb421 to a C-terminal region of p53,
binding of small peptides [23], deletion of a 30 amino acid
long sequence of the C-terminus of p53 as well as phospho-
rylation of p53 by protein kinase CK2 at residue 392 activates
p53 for a speci¢c DNA binding.
Protein kinase CK2, formerly known as casein kinase 2, not
only phosphorylates p53 at the C-terminus but also binds to
p53 [24]. The protein kinase CK2 consists of two catalytic K-
or KP-subunits and two regulatory L-subunits [25]. Mapping of
the interaction between p53 and CK2 revealed that p53 binds
to the regulatory L-subunit and not to the catalytic K-subunit
[26]. The L-subunit of CK2 binds to a C-terminal region of
p53 where a variety of other proteins such as p34cdc2, the
E4orf6 and tms1 bind [27^29]. Binding of the C-terminus of
p53 to the CK2 holoenzyme stimulates the kinase activity of
CK2 with respect to the phosphorylation of mdm2 [30]. On
the other hand binding of the L-subunit of CK2 to p53 re-
duced the DNA binding activity of p53 at least in vitro in a
dose dependent manner [31]. We now analysed whether the
regulatory L-subunit of CK2 might also in£uence the tran-
scriptional activity of p53.
We found that p53 expressed in mammalian cells binds to a
consensus DNA sequence and the L-subunit of CK2 had an
inhibitory e¡ect on this DNA binding activity of p53. In
COS1 cells we could show that coexpression of CK2 with
p53 reduced the transactivation activity to at least 50% with
mdm2, p21 and cyclin G promoters, while the bax promoter
remained una¡ected. The coexpression of the CK2 L-subunit
had no e¡ect on p53 mediated transrepression of the fos pro-
moter. Using SaosS138V21 and MCO1 cells we showed that
transactivation from all promoters was repressed by coexpres-
sion of the CK2 L-subunit.
2. Materials and methods
2.1. Cell culture
MCO1 cells (kindly provided by Moshe Oren) were grown in Dul-
becco’s modi¢ed Eagle’s medium (DMEM) supplemented with 10%
foetal calf serum (FCS) [32]. Hep3B cells [33], a mouse cell line which
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lacks endogenous mouse p53, COS1 cells, an SV40 transformed mon-
key cell line expressing wild-type p53 [34,35] and SaosS138V21 [36]
were cultured in DMEM supplemented with 5% FCS. SaosS138V21 is
a human osteosarcoma cell line lacking endogenous p53 [37] which
was stably transfected with temperature sensitive human p53, Val-138
[36]. MCO and SaosS138V21 cells were grown to subcon£uency and
then shifted to 32‡C for the indicated time period, control cells were
cultured at 37‡C.
2.2. Extraction of cells
Cells were harvested, washed three times with PBS (phosphate bu¡-
ered saline, pH 7.3) and resuspended in lysis bu¡er (100 mM Tris-
HCl, pH 9.0, 100 mM NaCl, 0.5% (v/v) NP40, 1% Trasylol). After
three freeze thaw cycles and sonication for 30 s, proteins were ex-
tracted 30 min on ice. Cell debris was eliminated by centrifugation
(4‡C, 30 min, 13 000Ug).
2.3. Western blot analysis
Proteins were separated on a 12.5% SDS polyacrylamide gel as
previously described [38], blotted to a PVDF membrane (Boehringer
Mannheim, Germany) and assayed by the appropriate antibody using
the ECL system (Amersham, Braunschweig, Germany) according to
the manufacturer’s instructions.
2.4. Antibodies
For the immunodetection of tagged CK2 L-subunit we used mono-
clonal antibody 10C4 which is directed against a tag derived from the
yeast tms1 protein [39,40].
2.5. Plasmids
A wild-type p53 cDNA was cloned into pRcCMV (pRcCMV p53)
and the sequence was con¢rmed by DNA sequencing. The CK2 L-
cDNA [41] was ampli¢ed by PCR and cloned into pCMVES, a vector
with a 10C4 epitope tag (Schneider et al., submitted) and named
pCMVES-L. The luciferase constructs mdm2-luc, WAF-luc (p21), cy-
clin G-luc, and bax-luc were described earlier [42]. The hfos-luc re-
porter was a kind gift from Klaus Roemer, Homburg, Germany.
pCMV30 without insert was used as a control vector.
2.6. Transfection and reporter gene expression analysis
Transfection of cells (MCO1 and SaosS138V21) with the respective
plasmids was performed by the DEAE-Dextran method (COS1) [43]
or Hep38 with superfect transfection reagent (Qiagen, Duºsseldorf,
Germany) 1 day after seeding. Usually 1 Wg of p53, 1 Wg pCMVES
or pCMV30 and 2 Wg reporter plasmid were transfected per 6 cm dish
of Hep3B cells as indicated in the ¢gure legends. Cells were harvested
24 h post-transfection. For luciferase reporter assays cells were
washed three times with PBS and lysed on the dish with 200 Wl lysis
bu¡er (Promega, Heidelberg, Germany) for 15 min at room temper-
ature. The cell lysate was cleared by centrifugation (14 000Ug for
5 min). Twenty Wl of the lysate were mixed with 100 Wl luciferase
assay reagent and assayed in a scintillation counter according to
the Promega instruction manual. Unless indicated each assay was
performed in triplicate and repeated three to four times. Data are
presented as mean values with the respective standard deviation.
2.7. Electrophoretic mobility shift analysis (EMSA)
Hep3B cells were transfected with 2 Wg p53 and 2 Wg pCMV30, or
2 Wg p53 and pCMVES-L, harvested after 24 h with MF bu¡er (400
mM NaCl, 20% glycerol, 1 mM Na3 EDTA, 10 mM HEPES, pH 7.9)
and used for shift analysis. The assay was performed with 32P-labeled
consensus DNA as described earlier [31].
3. Results
In a previous study we have shown that the speci¢c DNA
binding activity of p53 was inhibited by the regulatory L-sub-
unit of CK2 in a dose dependent manner [31].
For these studies we used extracts from insect cells infected
with recombinant baculoviruses expressing p53 and puri¢ed
regulatory L-subunit of CK2 together with the DNA consen-
sus sequence [44]. We now wanted to analyse the in£uence of
the L-subunit of CK2 on the DNA binding activity of p53
when p53 and CK2 L were expressed together in mammalian
cells. Therefore, we transfected Hep3B cells with p53
(pRcCMVp53) together with a CK2 L-plasmid (pCMVES-L)
or with control plasmid (pCMV30). After 24 h cells were
harvested and the cell extracts were incubated with the
DNA consensus sequence 5P-(CCGGGCATGT)3-3P. DNA-
protein complexes were analysed on a polyacrylamide gel.
Fig. 1 shows that in cells transfected only with control plas-
mid no shift is detectable (lane 1). In cells transfected with the
p53 expression plasmid and control vector, DNA is shifted to
a higher molecular weight (lane 2). However, this shift is not
detectable in cells, which were cotransfected with the p53 ex-
pression plasmid and the CK2 L-expression plasmid (lane 3).
In agreement with our previously published data with p53
expressed in insect cells these data suggest an inhibitory e¡ect
of the CK2 L-subunit on the p53 DNA binding activity also in
mammalian cells.
Sequence speci¢c DNA binding is prerequisitory for p53
mediated transactivation. Therefore, we wanted to investigate
the in£uence of the CK2 L-subunit on p53 mediated trans-
activation. For this type of analysis we used mdm2-luc, cyclin
G-luc, WAF1-luc and bax1-luc reporter constructs which were
already previously used for the analysis of p53 transactivation
function [42].
We cotransfected COS1 cells with the p53 expression plas-
mid and the pCMV30 control vector or the p53 expression
plasmid and the CK2 L-expression plasmid together with one
of the luciferase reporter plasmids as indicated in Fig. 2A.
Luciferase activity was measured in three di¡erent experi-
ments where the activity of a promoter in the absence of
CK2 L-subunit was regarded as 100%. As shown in Fig. 2A
the reporter activity from the mdm2, cyclin G and
p21WAF1=CIP1 promoter was reduced to about 50% when
CK2 L-subunit was expressed together with p53, whereas
the transcription of the bax promoter was not a¡ected (Fig.
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Fig. 1. DNA bandshift analysis with Hep3B cells transfected either
with control vector (lane 1), p53 with control vector (lane 2), or
p53 with CK2 L-subunit (lane 3). This ¢gure represents one of three
independent experiments. The arrow indicates supershifted 32P-la-
beled DNA of the consensus sequence 5P-(CCGGGCATGT)3-3P.
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Fig. 2. Transactivation of the mdm2, p21WAF1=CIP1, bax and cyclin G promoter in: A: COS1 cells; B: MCO1 cells; and C: SaosS138V21 cells.
Cells were cotransfected with the reporter plasmid, p53 and control vector, or p53 and CK2 L-plasmid. COS1 cells were kept at 37‡C whereas
MCO1 and SaosS138V21 cells were shifted to 32‡C. Cells were harvested after 24 h and analysed for luciferase activity as described in Section
2. Luciferase activity of cells transfected with p53 and control vector was set to 100%.
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2A). Coexpression of the K- or KP-subunit had no e¡ect (data
not shown).
Since it was shown that the activity of p53 dependent pro-
moters can be in£uenced di¡erently in di¡erent cell lines [42],
we tested if this would also be true for the inhibitory e¡ect of
CK2 L-subunit on the p53 mediated transactivation. For this
type of analysis we used either a mouse cell line which lacks
endogenous mouse p53 and which was stably transfected with
temperature sensitive mouse p53 (tsp53 135 Ala-Val (MCO1))
[32] or a human osteosarcoma cell line which lacks also en-
dogenous human p53 but expresses a temperature sensitive
human p53 Val-138 (SaosS138V21) [36]. At 37‡C both cell
lines express the mutant form and at 32‡C the wild-type
form of p53. We transfected the two cell lines with either
control vector (pCMV30) and reporter constructs, or the
CK2 L-expression plasmid with reporter constructs as indi-
cated. After transfection cells were shifted to 32‡C to activate
wild-type p53. Twenty-four h post-transfection cells were har-
vested and assayed for luciferase activity. For MCO1 cells
results of three di¡erent experiments are shown in Fig. 2B.
In the presence of the CK2 L-subunit the activity of all re-
porter constructs is repressed. The inhibition varies from
about 58% for the mdm2 reporter construct to 85% for the
cyclin G reporter construct. In contrast to our results ob-
tained with COS1 cells the bax promoter is repressed in
MCO1 cells.
The same experiment was performed with the SaosS138V21
cells and the results of three di¡erent experiments are shown
in Fig. 2C. As with MCO1 cells in the presence of the CK2 L-
subunit the reporter activity was repressed from all promoters
including the bax promoter. The repression varied between
about 60% with the cyclin G promoter and 90% with the
p21WAF1=CIP1 promoter. These results show that the extent
of the inhibitory e¡ect of the CK2 L-subunit on p53 mediated
transactivation from various promoters is dependent on the
cell line, but speci¢c and detectable in all three investigated
cell lines.
To show the speci¢city of the inhibition, we transfected
COS1 cells with increasing amounts of the CK2 L-expression
plasmid and constant amounts of the p53 expression plasmid,
harvested the cells and assayed half of the cell extract for
luciferase activity. The other half of the extract was used for
a Western blot analysis. As shown in Fig. 3A luciferase activ-
ity from the mdm2 promoter after coexpression of increasing
amounts of the CK2 L-subunit decreased in a dose dependent
manner. Fig. 3B shows the corresponding Western blot anal-
ysis, which demonstrates the increase in the amount of CK2 L
correlating with a decline in p53 transactivation activity. The
amount of CK2 L was quantitated by densitometry from the
corresponding Western blot showing that the amount of CK L
increased by a factor of 3.5 (lane 3) and 10.8 (lane 4) com-
pared to lane 2.
p53 not only transactivates a number of di¡erent promoters
but also transrepresses several genes, i.e. the c-fos gene [19].
Now, we wanted to know if this inhibitory e¡ect of the L-
subunit is restricted to p53 mediated transactivation activity
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Fig. 3. Concentration dependent inhibition of the p53 transactivated mdm2 promoter by increasing amounts of CK2 L. COS1 cells were trans-
fected with 10 Wg p53 and either control vector (lane 1) or 5 Wg (lane 2), 7 Wg (lane 3) and 10 Wg (lane 4) of the CK2 L-plasmid in 10 cm
dishes. Cells were harvested for luciferase assay and Western blot analysis. One of ¢ve independent experiments is shown. A: Luciferase assay.
B: Western blot analysis. 100 Wg of cell extract were subjected to SDS polyacrylamide gel electrophoreses and blotted onto PVDF membrane.
The epitope tagged L-subunit of CK2 was detected by 10C4 antibody.
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or if the transrepression activity is also a¡ected. We trans-
fected COS1 cells only with control vector pCMV30, with
p53 expression plasmid and pCMV30 control vector or the
p53 expression plasmid and the CK2 L-expression plasmid
together with a fos luciferase reporter (hfos-luc). Half of the
cell extract was used for the measurement of the luciferase
activity, the other half of the cell extract was analysed for
the expression of p53 and CK2 L by Western blot analysis
(data not shown). Although we found constant amounts of
p53 and CK2 L the results of four di¡erent experiments re-
vealed that p53 represses the reporter activity to about 50%
and that this repression is not a¡ected by coexpression of the
CK2 L-subunit (Fig. 4). This ¢nding strongly con¢rms the
speci¢city of the inhibitory e¡ect on the transactivation activ-
ity of p53, while the transrepression activity of p53 remains
una¡ected.
4. Discussion
The growth suppressor p53 functions as a transcriptional
transactivator protein with a sequence speci¢c DNA binding
activity [8,9,45]. In addition p53 interacts with various mem-
bers of the general transcription machinery including mem-
bers of the TFIID complex such as the TATA-box binding
protein (TBP) [46], TAFII40 and TAFII60 [47] and the TFIIH
transcriptional complex [48]. The domain for speci¢c DNA
binding is located in the central part of the p53 polypeptide
chain whereas the transcription factor activity was localised in
the N-terminal acidic domain of the p53 molecule. The C-
terminus of p53 confers a non-speci¢c DNA binding activity
and it seems to regulate the speci¢c DNA binding activity
[21]. p53 is phosphorylated by protein kinase CK2 at the
penultimate residue [49] and this phosphorylation activates
the speci¢c DNA binding activity of p53 [50,51]. Protein kin-
ase C phosphorylates p53 at several C-terminal residues at
least in vitro and this phosphorylation again stimulates the
sequence speci¢c DNA binding activity of p53 [52^54]. Bind-
ing of the monoclonal antibody PAb421 to C-terminal se-
quences and a deletion of the last 30 amino acids of p53
also activates p53 for sequence speci¢c DNA binding [50].
Some years ago, we found that protein kinase CK2 not only
phosphorylates p53 but also binds via the regulatory L-sub-
unit to p53 [24,26,55]. The binding region for CK2 on the
polypeptide chain of p53 was recently mapped to a region
between amino acids 330^339 [29], a region where several
other proteins such as p34cdc2, tms1, protein kinase C and
the E4orf6 protein bind [27,28,56]. Binding of CK2 L to this
region of the p53 molecule leads to a dose dependent reduc-
tion in the DNA binding activity of p53 which was expressed
either in insect cells [31] or in mammalian cells as shown here
(Fig. 1).
Since it was described that the adenovirus E4orf6 protein
not only interacts with C-terminal sequences of the p53 mol-
ecule but also blocks p53 mediated transcriptional activity [56]
we asked in the present study whether the L-subunit of CK2
might also block transcription mediated by p53. For the
transactivation assays we used luciferase reporter gene con-
structs driven by the mdm2, p21WAF1=CIP1, bax or cyclin G
promoter which were previously used to analyse the e¡ects of
phosphorylation of rat p53 on transactivation [42]. It is gen-
erally accepted that a major control by p53 on the cell cycle at
G1/S phase is through transcriptional control of the
p21WAF1=CIP1 gene [57]. p21WAF1=CIP1 is an e¡ective inhibitor
of G1/S cyclin dependent kinases (cdks) [58]. Cyclin G is an-
other transcriptional target of p53 [16] which upon overex-
pression also enhances cell cycle progression. A p53 DNA
binding sequence has also been found in the bax gene pro-
moter [59] and after DNA damage and overexpression of p53
the expression of bax is known to increase. There is ample
evidence that bax may be part of a p53 dependent apoptosis
pathway [60]. Finally, the mdm2 gene is also regulated by p53.
The mdm2 gene product is implicated in a regulatory network
which controls the subcellular tra⁄cking and the expression
of p53 [61]. Transactivation of the mdm2, p21WAF1=CIP1 and
cyclin G promoter by p53 was down-regulated by coexpres-
sion of the L-subunit of CK2 regardless of which cell line was
used. It is striking that only transactivation of the bax pro-
moter by p53 is not a¡ected in COS1 cells whereas a consid-
erable decrease was observed in the two other cell lines. Cell
type speci¢c variations in transcriptional activities of p53 have
been described earlier [42,62,63]. We now present evidence for
a cell type speci¢c repression of the p53 transactivation func-
tion by the L-subunit of CK2.
p53 not only transactivates gene expression but also can
transrepress some genes such as the c-fos gene [64]. As shown
in the present study the in£uence of the L-subunit of CK2
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Fig. 4. In£uence of CK2 L-subunit on the transrepression activity of p53. COS1 cells were transfected with hfos-luc, control vector, or p53
with CK2 L-subunit. Luciferase activity of cells transfected with hfos-luc and control vector was set to 100%.
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seems to be restricted to an in£uence on the transactivation
and not on the transrepression function of p53.
CK2 isolated from a wide variety of organisms and tissues
consists of a spontaneously active heterotetramer composed of
two catalytic subunits (K- and/or KP-subunits) and two regu-
latory L-subunits. It is an intriguing question whether there is
additional K- or L-subunit which is not in the heterotetramer
of the holoenzyme. Since we found a distinct inhibitory func-
tion of the L-subunit for the DNA binding activity of p53
which is di¡erent from the activity of the holoenzyme, these
experiments might argue for the presence of at least uncom-
plexed L-subunit. This hypothesis is strengthened by the fact
that the free subunits of CK2 are transported separately to the
nucleus where they are assembled [65]. Furthermore, binding
partners for the CK2 K such as hsp 90, nucleolin and PP2A as
well as for the CK2 L such as Nopp140, A-raf or p53 were
described [66^71], indicating that both subunits have individ-
ual functions which are di¡erent from their function in the
holoenzyme. Finally, in human kidney tumour cells as well as
in lymphoid cell lines an asymmetric expression of protein
kinase CK2 subunits were described [72,73]. Elevated levels
of CK2 are found in highly proliferating cells in comparison
to normal proliferating cells (for review see [25]). According to
our present results elevated levels of CK2 L would mean that
transactivation of p53 dependent genes such as p21WAF1=CIP1
is reduced which would favour cell growth. Our results might
further indicate a dual role of protein kinase CK2 in regulat-
ing p53 functions. Phosphorylation of p53 by CK2 stimulates
DNA binding and transactivation functions of p53 whereas
binding of the regulatory L-subunit of CK2 to p53 seems to
have the opposite e¡ect, i.e. the CK2 L-subunit reduces the
DNA binding activity and the transactivation function of p53.
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